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BACKGROUND: Life expectancy in the United States has recently declined, in part attributable to premature cardiometabolic 
mortality. We characterized national trends in premature cardiometabolic mortality, overall, and by race-sex groups.
METHODS AND RESULTS: Using death certificates from the Centers for Disease Control and Prevention’s Wide-Ranging Online 
Data for Epidemiologic Research, we quantified premature deaths (<65 years of age) from heart disease, cerebrovascular 
disease, and diabetes mellitus from 1999 to 2018. We calculated age-adjusted mortality rates (AAMRs) and years of potential 
life lost (YPLL) from each cardiometabolic cause occurring at <65 years of age. We used Joinpoint regression to identify an 
inflection point in overall cardiometabolic AAMR trends. Average annual percent change in AAMRs and YPLL was quantified 
before and after the identified inflection point. From 1999 to 2018, annual premature deaths from heart disease (117 880 to 
128 832), cerebrovascular disease (18 765 to 20 565), and diabetes mellitus (16 553 to 24 758) as an underlying cause of death 
increased. By 2018, 19.7% of all heart disease deaths, 13.9% of all cerebrovascular disease deaths, and 29.1% of all diabetes 
mellitus deaths were premature. AAMRs and YPLL from heart disease and cerebrovascular disease declined until the inflec-
tion point identified in 2011, then remained unchanged through 2018. Conversely, AAMRs and YPLL from diabetes mellitus 
did not change through 2011, then increased through 2018. Black men and women had higher AAMRs and greater YPLL for 
each cardiometabolic cause compared with White men and women, respectively.
CONCLUSIONS: Over one-fifth of cardiometabolic deaths occurred at <65 years of age. Recent stagnation in cardiometabolic 
AAMRs and YPLL are compounded by persistent racial disparities.
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In 2005, a controversial forecast predicted that the growing prevalence of obesity and diabetes melli-tus (DM) would reduce life expectancy in the United 
States after 2010.1 In fact, life expectancy did indeed 
stall in 2010 and has fallen since 2014 in the United 
States.2 This unprecedented decline after decades of 
increasing life expectancy has been largely attributed 
to an increase in premature mortality among younger 
adults (<65  years of age). Associated health dispari-
ties across race, sex, and geographic subgroups have 
also worsened over the past decade.2,3 Accordingly, 
greater attention has turned to understanding the 
causes of premature mortality.4,5 Cardiometabolic dis-
eases, including heart disease (HD), cerebrovascular 
disease (CBD), and DM, remain the leading causes of 
premature death in the United States, yet are largely 
preventable.6,7
Premature mortality has broad economic and 
societal consequences, in terms of lost productivity 
and impact on family support units and communities. 
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The United Nations Sustainable Development Goals 
therefore outlined a global objective to reduce pre-
mature mortality from noncommunicable diseases, 
including cardiometabolic diseases, by one-third.8 
Such a target provides an important framework to 
develop and implement clinical and public health 
prevention strategies to equitably address premature 
mortality at the population, community, and individ-
ual level. To inform potential strategies, we quantified 
recent US trends in premature mortality from HD, 




All data and materials are publicly available in the Centers 
for Disease Control and Prevention’s Wide-Ranging 
Online Data for Epidemiologic Research (CDC WONDER) 
database at https://wonder.cdc.gov. Premature cardio-
metabolic deaths were quantified using death certificate 
records from the CDC WONDER database.9 International 
Classification of Diseases, Tenth Revision (ICD-10) codes 
were used to identify decedents <65  years of age at 
time of death from HD (I00–I09, I11, I13, I20–I51), CBD 
(I60–I69), or DM (E10–E14) as underlying cause of death. 
Premature mortality in the United States was defined as 
deaths at <65 years of age(versus <70 years of age, as 
defined in the United Nations Sustainable Development 
Goals8) to align with prior analyses of premature mortality 
in the United States that informed this analysis2 as well as 
the fact that current life expectancy is <70 years of age 
for certain groups of the population. Secondary analysis 
evaluated mortality from DM as either an underlying or 
contributing cause of death in CDC WONDER multiple-
cause-of-death files to more broadly quantify the bur-
den of DM-related mortality, as DM also contributes to 
death from other underlying causes. The proportion of 
all deaths from cardiometabolic causes that occurred at 
<65 years of age, as well as the proportion of all deaths 
that occurred at <65 years of age that were attributable 
to cardiometabolic causes, was calculated.
Premature deaths were ascertained overall (all 
race groups) and separately in race-sex subgroups 
(Black and White women and men). Other race/ethnic 
groups (Asian Americans, Native Americans, Hispanic 
Americans) were not evaluated because of less reli-
able identification of these groups on death certificate 
records.10–12 In secondary subgroup analyses, trends 
in age-adjusted mortality rate (AAMR) from premature 
cardiometabolic deaths was also evaluated by cen-
sus region in the United States (Northeast, Midwest, 
South, and West) and by county-level urbanization 
(rural: micropolitan, noncore regions; urban: large cen-
tral metro, large fringe metro, medium metro, small 
metro regions).13
Age-Adjusted Mortality Rates
AAMRs were calculated per 100  000 population 
for each cardiometabolic cause in each study year 
using the AAMR query embedded in CDC WONDER. 
AAMRs were adjusted to the 2000 US standard 
population. AAMR ratios were calculated by race to 
indicate the number of deaths in Black individuals 
for every 1 death in White individuals per 100  000 
population. Temporal trends in AAMRs were char-
acterized by fitting log-linear regression models 
with Joinpoint Regression Program version 4.7.0.0 
(National Cancer Institute).14 Joinpoint Regression 
identified an inflection point in cardiometabolic 
AAMR trends in 2011, consistent with prior reports 
of trends in overall cardiometabolic disease.15,16 This 
inflection point was applied for all subgroups. To 
CLINICAL PERSPECTIVE
What Is New?
• Between 1999 and 2018, over one-fifth of car-
diometabolic deaths in the United States oc-
curred prematurely (<65 years of age) with 
persistent Black-White disparities; the propor-
tion of cardiometabolic deaths occurring pre-
maturely increased over time, with increases in 
mortality rates from premature cerebrovascular 
disease and diabetes mellitus.
What Are the Clinical Implications?
• The burden of premature mortality from heart 
disease, cerebrovascular disease, and diabetes 
mellitus is high in the United States and high-
lights the need for implementation of evidence-
based management of clinical risk factors and 
public policy targeting high-burden groups 
to equitably reduce disparities in premature 
mortality.
Nonstandard Abbreviations and Acronyms
AAMR age-adjusted mortality rate
CBD cerebrovascular disease
CDC WONDER Centers for Disease Control 
and Prevention’s Wide-Ranging 





YPLL years of potential life lost
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evaluate trends in AAMRs, average annual percent-
age change in AAMRs was calculated before and 
after the inflection point, that is, from 1999 to 2011, 
and from 2011 to 2018.
Years of Potential Life Lost
Years of potential life lost (YPLL) were calculated 
using standard methods previously described for 
various reference age points.17,18 YPLL was calculated 
for premature deaths that occurred before 65 years 
of age (YPLL <65). For comparison, YPLL was sec-
ondarily calculated for deaths that occurred younger 
than overall life expectancy (LE) as well as race-sex 
subgroup-specific LE (YPLL<LE), as an estimate of 
actual years lost. For YPLL <65, age 65 was used 
as the reference age for YPLL calculations. For 
YPLL<LE, an average LE between 1999 and 2018 
for the total US population, and individually for each 
race-sex subgroup, was calculated using US vital 
statistics reports.19,20 This subgroup-specific aver-
age LE was used as the reference age for YPLL<LE 
calculations in each individual race-sex subgroup.19,20 
For each year of the study period, YPLL was calcu-
lated by multiplying the number of deaths from the 
respective cardiometabolic cause in each of a series 
of 5-year age groups decrementing from the refer-
ence age, by the difference between the reference 
age and the midpoint age of death within each 5-year 
age group. This result was divided by the total 5-year 
age group population, then multiplied by 100 000 to 
obtain YPLL per 100 000 population. YPLL was then 
age-standardized to the 2000 US standard popula-
tion. The sum of YPLL from each 5-year age group of 
decedents within each study year provided YPLL per 
100 000 in the total population and in race-sex sub-
groups for each year of analysis. Trends in YPLL were 
evaluated using Joinpoint Regression with the meth-
ods described above for AAMRs. Average annual 
percent change of YPLL was calculated from 1999 to 
2011 and from 2011 to 2018. YPLL ratios were calcu-
lated by race to indicate the number of YPLL in Black 
individuals for every 1  year lost in White individuals 
per 100 000 population.
For tests of significance a 2-sided P<0.05 indicated 
statistical significance. Requirements for institutional 
review committee approval or informed consent were 
waived because deidentified publicly available data 
were used.
RESULTS
From 1999 to 2018, the number of premature deaths 
increased each year from HD (117 880 to 128 832), CBD 
(18 765 to 20 565), and DM (16553 to 24 758) (Table 1). 
Thus, by 2018, cardiometabolic deaths accounted for 
23.5% (174 155/739 798) of all premature deaths, (HD, 
CBD, and DM accounting for 17.4% [128 832 deaths], 
2.8% [20 565 deaths], and 3.3% [24 758 deaths], 
Table 1. Number of Premature Cardiometabolic Deaths (<65 Years of Age) as a Percentage of All Cardiometabolic Deaths 
(All Ages), 1999 to 2018
1999 2011 2018
Heart disease, No. deaths <65 y/No. deaths of all ages (%)
Total 117 880/725 192 (16.3) 121 453/596 577 (20.4) 128 832/655 381 (19.7)
Black women 9195/40 998 (22.4) 9259/33 459 (27.7) 10 501/38 356 (27.4)
White women 25 908/327 533 (7.9) 26 446/248 105 (10.7) 27 685/253 786 (10.9)
Black men 14 876/37 576 (39.6) 15 894/34 913 (45.6) 18 431/43 713 (42.2)
White men 65 194/307 585 (21.2) 66 229/265 596 (24.9) 67 571/299 229 (22.6)
Cerebrovascular disease, No. deaths <65 y/No. deaths of all ages (%)
Total 18 765/167 366 (11.2) 19 607/128 932 (15.2) 20 565/147 810 (13.9)
Black women 2364/10 990 (21.5) 2213/8814 (25.1) 2266/10 753 (21.1)
White women 5866/89 960 (6.5) 5849/65 278 (9.0) 5996/70 703 (8.5)
Black men 2674/7894 (33.9) 2905/7039 (41.3) 3027/8971 (33.7)
White men 7019/54 867 (12.8) 7579/43 264 (17.5) 8097/50 967 (15.9)
Diabetes mellitus, N deaths <65 y/N deaths of all ages (%)
Total 16 553/68 399 (24.2) 21 429/73 831 (29.0) 24 758/84 946 (29.1)
Black women 2073/7168 (28.9) 2228/6847 (32.5) 2497/7562 
(33.0)
White women 5028/29 054 (17.3) 5859/27 191 (21.5) 6283/27 805 (22.6)
Black men 2034/4759 (42.7) 2764/6048 (45.7) 3515/7935 
(44.3)
White men 6866/25 545 (26.9) 9700/30 783 (31.5) 11 196/37 262 (30.0)
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respectively, of 739 798 deaths total; Table  S1). By 
2018, premature HD deaths accounted for 19.7% 
(128 832/655 381) of all HD deaths, premature CBD 
deaths accounted for 13.9% (20 565/147 810) of all 
CBD deaths, and premature DM deaths accounted 
for 29.1% (24 758/84 946) of all DM deaths. Black 
men had the highest proportion of cardiometabolic 
deaths that occurred prematurely (42.2% of HD deaths 
[18 431/43 713], 33.7% of CBD deaths [3027/8971], 
and 44.3% of DM deaths [3515/7935]) compared with 
other race-sex groups.
Age-Adjusted Mortality Rates
AAMRs from premature cardiometabolic diseases 
are shown in Table 2 and Figure S1. From 1999 to 
2011, overall AAMRs from premature HD declined 
2.3% per year (95% CI, −2.4 to −2.1; P<0.05) from 
49.4 to 37.5 deaths per 100 000. After 2011 through 
2018, there was no change in AAMRs from prema-
ture HD. From 1999 to 2011, AAMRs from premature 
CBD declined 2.3% per year (95% CI, −2.5 to −2.1; 
P<0.05) from 7.9 to 6.0 deaths per 100 000, but did 
not change after 2011. AAMRs from premature DM 
remained unchanged from 1999 to 2011, then in-
creased 1.7% per year (95% CI, 1.2–2.1) to 7.3 deaths 
per 100 000 in 2018.
Similar patterns were seen in all race-sex groups. 
AAMRs declined for HD and CBD in all race-sex 
groups through 2011. After 2011, HD AAMRs signifi-
cantly increased in White women but remained un-
changed for other groups. After 2011, CBD AAMRs 
declined at a slower rate in Black individuals com-
pared with pre-2011, and stagnated in White individ-
uals. For DM, AAMRs declined in Black and White 
women and remained unchanged in Black and White 
men before 2011. After 2011, AAMRs from DM in-
creased for all groups except Black women, in whom 
AAMRs remained stagnant. For all cardiometabolic 
causes, Black individuals experienced ≈2-fold higher 
absolute AAMRs compared with White individuals. In 
2018, HD AAMR ratio was 2.2 in women and 1.8 in 
men, CBD AAMR ratio was 2.2 in women and 2.5 in 
Table 2. Age-Adjusted Mortality Rates From Premature Deaths (<65 Years of Age) Attributable to Each Cardiometabolic 
Disease Subtype as Underlying Cause of Death, 1999 to 2018
AAMR per 100 000 Average APC in AAMR
1999 2011 2018 1999–2011 2011–2018
Heart disease deaths <65 y
Total 49.4 37.5 37.6 −2.3 (−2.4 to −2.1)* 0.0 (−0.2 to 0.2)
Black women 64.8 44.1 44.8 −3.1 (−4.0 to −2.3)* 0.3 (−0.4 to 1.0)
White women 25.1 19.7 20.0 −1.9 (−2.2 to −1.7)* 0.4 (0.1 to 0.8)*
AAMR ratio (women) 2.6 2.2 2.2
Black men 125.7 87.7 90.7 −3.0 (−3.2 to −2.7)* 0.2 (−0.4 to 0.8)
White men 65.8 50.5 49.6 −2.2 (−2.3 to −2.1)* −0.2 (−0.5 to 0.0)
AAMR ratio (men) 1.9 1.7 1.8
Cerebrovascular disease deaths <65 y
Total 7.9 6.1 6.0 −2.3 (−2.5 to −2.1)* 0.0 (−0.5 to 0.5)
Black women 16.6 10.6 9.6 −3.5 (−4.2 to −2.8)* −1.6 (−2.6 to −0.7)*
White women 5.7 4.4 4.4 −2.4 (−2.6 to −2.1)* 0.1 (−0.6 to 0.8)
AAMR ratio (women) 2.9 2.4 2.2
Black men 22.7 15.9 14.7 −3.1 (−3.9 to −2.3)* −1.0 (−1.6 to −0.4)*
White men 7.1 5.8 6.0 −1.7 (−2.1 to −1.4)* 0.7 (0.0 to 1.4)
AAMR ratio (men) 3.2 2.7 2.5
Diabetes mellitus deaths <65 y
Total 6.9 6.6 7.3 −0.5 (−1.1 to 0.1) 1.7 (1.2 to 2.1)*
Black women 14.8 10.6 10.8 −3.0 (−4.6 to −1.3)* 0.7 (0.0 to 1.3)
White women 4.9 4.3 4.6 −1.4 (−2.4 to −0.5)* 1.5 (0.9 to 2.0)*
AAMR ratio (women) 3.0 2.5 2.3
Black men 17.3 15.2 17.4 −1.1 (−2.9 to 0.8) 2.0 (0.5 to 3.4)*
White men 6.9 7.4 8.3 0.3 (−0.1 to 0.8) 2.2 (1.8 to 2.5)*
AAMR ratio (men) 2.5 2.1 2.1
AAMR ratio indicates number of deaths in Black individuals for every 1 death in White individuals per 100 000 population. AAMR indicates age-adjusted 
mortality rate; and APC, annual percent change (95% CI).
*Indicates that the average APC is significantly different from zero; P<0.05.
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men, and DM AAMR ratio was 2.3 in women and 2.1 
in men.
Years of Potential Life Lost
Table 3 and the Figure show patterns in YPLL as a 
consequence of premature death from each under-
lying cardiometabolic cause of death. From 1999 
to 2011, YPLL <65 from HD declined from 512.2 to 
415.5  years per 100  000 (1.7% per year; 95% CI, 
−2.0 to −1.5; P<0.05), and thereafter remained rel-
atively unchanged through 2018. YPLL <65 from 
CBD declined from 87.0  year per 100  000 in 1999 
to 69.9 years per 100 000 in 2018 (−1.8% per year; 
95% CI, −2.2 to −1.5; P<0.05), then did not change 
through 2018. YPLL <65 from DM remained un-
changed from 1999 to 2011, then increased 2.4% per 
year (95% CI, 1.9–2.9; P<0.05) to 82.3 years lost per 
100 000 in 2018.
Across all race-sex groups, YPLL <65 from HD 
and CBD significantly declined from 1999 to 2011 with 
fastest rate of decline in Black men and women. From 
2011 to 2018, YPLL <65 from HD declined at a slower 
rate in White men but did not change in other groups. 
YPLL <65 from CBD decreased in Black men and 
women from 2011 to 2018. YPLL <65 from DM de-
creased in Black women and was unchanged in White 
women, Black men, and White men from 1999 to 2011. 
After 2011, YPLL <65 from DM increased for all race-
sex groups. For all cardiometabolic causes, Black indi-
viduals experienced at least twice the number of YPLL 
per 100 000 compared with White individuals. In 2018, 
YPLL ratio for HD was 2.3 in women and 2.0 in men, 
for CBD was 2.3 in women and 2.4 in men, and for 
DM was 2.5 in women and 2.2 in men. YPLL <65 ac-
counted for a large proportion of total YPLL<LE, which 
is shown in the Figure and Table S2. Comparison of 
YPLL<LE and YPLL <65 annual percent change CIs 
indicates that from 1999 to 2011, YPLL<LE from HD 
and CBD declined at a faster rate than their respec-
tive YPLL <65 trends, with no significant difference in 
YPLL<LE and YPLL <65 trend for DM. After 2011, an-
nual percent change of YPLL<LE and YPLL <65 had 
Table 3. Years of Potential Life Lost From Premature Deaths (<65 Years of Age) Attributable to Each Cardiometabolic 
Disease Subtype as Underlying Cause of Death, 1999 to 2018
YPLL per 100 000 Average APC in YPLL
1999 2011 2018 1999–2011 2011–2018
Heart disease deaths <65 y
Total 512.2 415.5 407.6 −1.7 (−2.0 to −1.5)* −0.1 (−0.4 to 0.2)
Black women 716.7 518.2 516.9 −2.8 (−3.1 to −2.4)* −0.2 (−1.0 to 0.7)
White women 253.5 219.1 220.5 −1.2 (−1.5 to −1.0)* 0.5 (0.0 to 1.0)
YPLL ratio (women) 2.8 2.4 2.3
Black men 1350.0 987.0 1018.9 −2.5 (−3.1 to −1.9)* 0.3 (−0.4 to 0.9)
White men 663.1 542.1 513.1 −1.7 (−1.9 to −1.6)* −0.7 (−1.1 to −0.3)*
YPLL ratio (men) 2.0 1.8 2.0
Cerebrovascular disease deaths <65 y
Total 87.0 69.9 67.9 −1.8 (−2.2 to −1.5)* −0.5 (−2.2 to 1.3)
Black women 190.9 126.3 109.2 −3.6 (−4.4 to −2.8)* −1.9 (−3.3 to −0.5)*
White women 62.1 49.4 47.2 −1.9 (−2.1 to −1.6)* −0.4 (−1.2 to 0.4)
YPLL ratio (women) 3.1 2.6 2.3
Black men 238.2 173.2 158.4 −2.8 (−3.7 to −1.8)* −1.2 (−1.8 to −0.5)*
White men 75.6 64.6 65.6 −1.2 (−1.6 to −0.8)* 0.3 (−0.9 to 1.5)
YPLL ratio (men) 3.2 2.7 2.4
Diabetes mellitus deaths <65 y
Total 71.1 71.0 82.3 −0.2 (−0.8 to 0.4) 2.4 (1.9 to 2.9)*
Black women 143.3 117.0 131.7 −1.9 (−3.5 to −0.3)* 1.8 (1.1 to 2.4)*
White women 49.6 46.6 51.9 −0.7 (−1.5 to 0.1) 1.9 (1.4 to 2.4)*
YPLL ratio (women) 2.9 2.5 2.5
Black men 178.8 161.1 200.5 −1.0 (−2.2 to 0.2) 3.1 (1.8 to 4.5)*
White men 71.8 78.3 89.8 0.5 (−0.1 to 1.1) 2.4 (1.9 to 2.9)*
YPLL ratio (men) 2.5 2.1 2.2
YPLL ratio indicates number of years of potential life lost in Black individuals for every 1 year of potential life lost in White individuals per 100 000 population. 
APC indicates annual percent change (95% CI); and YPLL, years of potential life lost.
*Indicates that the average APC is significantly different from zero; P<0.05.
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overlapping CIs for HD, CBD, and DM, suggesting no 
significant difference in trend.
DM as Underlying or Contributing Cause
Secondary analyses evaluated DM as an underly-
ing or contributing cause of death (see Tables  S3 
and S4). In 2018, there were 65 932 premature DM-
related deaths, representing 23.9% of all DM-related 
deaths of any age, and 8.9% of all premature deaths. 
Overall YPLL <65 from DM as underlying or contrib-
uting cause was 193.8  years per 100 000 in 2018, 
and AAMR from DM-related deaths was 19.0 deaths 
per 100  000. Substantial disparities in YPLL and 
AAMRs from DM-related deaths were observed in 
race-sex groups.
Trends by Census Region and County-
Level Urbanization
Secondary analyses also examined AAMRs from prema-
ture cardiometabolic deaths stratified by census region 
and by county-level urbanization (see Tables S5 and S6 
and Figure S2). Patterns in AAMRs stratified by census 
region and by county-level urbanization were similar in 
comparison with overall trends. For HD and CBD, AAMR 
declines slowed or stagnated in all census regions and in 
both rural and urban counties after 2011. For DM, AAMRs 
either stagnated or increased in all census regions and 
in both rural and urban counties after 2011. AAMRs were 
consistently highest in the South compared with other 
regions, and higher in rural compared with urban coun-
ties, for all cardiometabolic causes.
DISCUSSION
Our analysis demonstrates increasing numbers of fatal 
cardiometabolic events in younger US adults <65 years 
of age. By 2018, approximately one-fifth of HD deaths, 
one-sixth of CBD deaths, and one-third of DM deaths 
occurred prematurely, which translated into ≈1.8 mil-
lion YPLL to cardiometabolic disease in the United 
States. Compared with 1999, there were 9% more 
premature HD deaths, 10% more premature CBD 
deaths, and 50% more premature DM deaths in 2018. 
AAMRs and YPLL from HD and CB declined between 
1999 and 2011, but were stagnant between 2011 and 
2018. DM AAMRs and YPLL were stagnant between 
1999 and 2011 and subsequently increased between 
2011 and 2018. Similar trends across time were seen 
in each race-sex and geographic subgroup. However, 
Black individuals, the southern US census region, and 
rural counties consistently had the highest burdens of 
premature cardiometabolic mortality.
Figure 1. Years of potential life lost before age 65 (premature) 
and before life expectancy from each cardiometabolic cause 
of death, 1999 to 2018.
A, Heart disease, (B) cerebrovascular disease, (C) diabetes 
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The patterns in premature cardiometabolic AAMR 
trends we observed are consistent with reports of 
stagnation or worsening in overall cardiometabolic 
AAMRs since 2011. However, we found that numbers 
of premature deaths from HD and CBD increased 
from 1999 to 2018, which contrasts with declining 
total deaths (all age groups) from these causes during 
this time.21 There was also a smaller magnitude of de-
cline in AAMR and YPLL between 1999 and 2011 in 
decedents <65 years of age as compared with overall 
population changes. Increases in highly preventable 
premature mortality from cardiometabolic causes have 
contributed a 3-fold greater absolute number of pre-
mature deaths compared with those from accidental 
drug overdose or suicide.2,4,9 Additionally, recent mod-
eling supports that stalling life expectancy in the United 
States since 2010 is predominantly attributable to car-
diovascular diseases.22 These findings suggest that re-
versal of the worrisome trends observed in premature 
cardiometabolic mortality may have the greatest effect 
in restoring LE growth.
Changing patterns in LE, consistent with prior fore-
casts from 2005,1 are likely in large part attributable 
to the increasing prevalence of underlying cardiomet-
abolic risk factors, including obesity,23,24 DM,23,25–27 
inadequate physical activity,28 and poor diet quality,29 
particularly among younger adults. Our findings quan-
tifying the growing burden of premature cardiomet-
abolic mortality highlight the large gaps that exist to 
achieve ambitious targets set by the United Nations 
Sustainable Development Goals program8 to reduce 
premature mortality by one-third and by the American 
Heart Association to equitably improve health-ad-
justed LE by 2 to 3 years.30 Anchoring the 2030 iter-
ation of the American Heart Association impact goals 
on health-adjusted LE emphasizes broader health pro-
motion earlier in the life course, and builds upon the 
cardiovascular health construct (dietary intake, smok-
ing, physical activity, blood glucose, blood pressure, 
cholesterol, and weight) developed in 2010.30 Multiple 
epidemiologic studies have since identified that tra-
jectories of decline in cardiovascular health begin as 
early as childhood and adolescence.31 Such patterns 
strongly suggest that health promotion and primordial 
cardiovascular disease prevention must be directed 
toward individuals earlier in the life course—not just in 
adults. Adolescence, childhood, infancy, in utero, and 
even preconception are each life stages during which 
cardiometabolic health must also be emphasized to 
reduce subsequent morbidity and mortality.32–35
We further show substantial and persistent race, 
sex, and geographic disparities in premature car-
diometabolic mortality. In the United States, prev-
alence of cardiovascular risk factors and disease is 
higher, and rates of control and optimal medical treat-
ment are lower in racial minority, socioeconomically 
disadvantaged, and lower education groups as well 
as in the southern states.36–38 One barrier that may 
contribute to adverse outcomes in adults <65 years 
of age is lack of access to health care. Notably, im-
plementation of the Affordable Care Act enacted in 
March 2010, which ostensibly broadened health insur-
ance coverage including for younger adults, does not 
appear to have led to national reductions in premature 
cardiometabolic mortality rates. Yet a recent analysis 
demonstrated that counties in states that expanded 
Medicaid eligibility had a significantly smaller increase 
in premature HD AAMRs compared with counties 
in nonexpansion states.39 These observations may 
suggest that having health insurance is necessary 
but not sufficient in improving access to care and im-
proving health. Access to care comprises more than 
just health insurance; available services, timeliness of 
care, and prescription medication coverage are also 
important components that may vary across commu-
nities. As medication cost remains a significant barrier 
and may contribute to lower rates of adherence and 
risk factor control, alternative delivery strategies such 
as a polypill have been proposed and were recently 
demonstrated to lead to greater reduction in systolic 
blood pressure and cholesterol in a randomized con-
trolled trial in low socioeconomic and minority com-
munities in the southern United States.40 Additionally, 
the suboptimal trends observed may have occurred 
in part because of health consequences related to 
the 2007 to 2009 economic recession in the United 
States and its consequent effects on employment, 
housing, access to health insurance, and other so-
cial determinants, which have been linked to increas-
ing cardiovascular morbidity and a range of adverse 
health outcomes.41
Both evidence-based dissemination and imple-
mentation strategies and broader policy interventions 
can complement efforts at the individual, community, 
and population levels to close gaps in cardiometa-
bolic mortality in those disproportionately affected.42 
Successful local health promotion program mod-
els that tailor to at-risk populations in diverse com-
munities have been developed in partnership with 
community stakeholders and nonphysician health 
workers. One successful example is the program for 
hypertension management in Black men conducted 
in barbershops,43 which leveraged the familiarity of 
barbers with their local communities in partnership 
with pharmacists, who prescribed antihypertensive 
medications, resulting in significantly better blood 
pressure compared with the study’s control group. 
Appropriate and intensive blood pressure lowering is 
one of the most impactful targets for reducing pre-
mature mortality. In fact, global models integrating 
risk factor data and mortality projections demon-
strate that increasing coverage of antihypertensive 
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medications to 70% might delay 39  million deaths. 
Dietary interventions reducing sodium intake by 30% 
and eliminating trans fatty acid intake could delay an-
other 54 million deaths.44 Policy interventions, such 
as taxation, may be a promising strategy to achieve 
these dietary goals, as preliminary data from the 
Sweetened Beverage Tax in Cook County, Illinois, 
demonstrated success in reduction of volume sold in 
response to taxation.45
Our analysis of premature cardiometabolic mortal-
ity has a number of limitations. First, we do not have 
data on individual-level risk factors. However, causal 
associations between traditional modifiable risk factors 
and premature mortality are already well established. 
Second, the absence of a national surveillance program 
in the United States limits our ability to estimate trends 
in health-adjusted LE. However, the use of YPLL is a 
particularly important metric of our analyses, because 
this measure uniquely captures the burden of prema-
ture mortality by placing greater weight on deaths that 
occur at younger ages. Third, our assessment of the 
US population is constrained by the limited race/ethnic-
ity data available in the CDC WONDER database be-
cause of either a small number of decedents or lack of 
disaggregated ethnic data (especially for Hispanic and 
Asian Americans). Fourth, death certificate data may 
be subject to miscoding or misclassification. However, 
such changes are unlikely to substantially alter the major 
mortality trends we observed over 2 decades. Despite 
limitations, we present the most comprehensive avail-
able data to evaluate trends in premature cardiometa-
bolic mortality in the United States.
Over one-fifth of cardiometabolic deaths are pre-
mature, occurring at <65 years of age. Recent stag-
nation in premature cardiometabolic AAMRs and 
YPLL, compounded by persistent disparities by race, 
sex, and region, reveal inadequate progress toward 
goals for cardiometabolic mortality reduction. This 
premature mortality is mostly preventable. Our find-
ings inform the need for potential strategies focusing 
on cardiometabolic health promotion policies and 
health maintenance prioritizing younger populations 
to achieve goals for long-term, equitable health out-
comes in all Americans.
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Table S1. Percent of all premature deaths (<65 years) that are cardiometabolic, 1999-2018. 
 
 Percent of premature deaths (<65 years) that are CM,  
N (%) 
 1999 2011 2018 
Deaths from all 
causes <65 years 
(denominator) 
   
   Total  593,712 683,502 739,798 
   Black women 47,935 51,059 56,199 
   White women 169,582 200,201 211,004 
   Black men 73,444 75,335 86,838 
   White men 285,620 332,649 355,215 
    
Heart disease  
deaths <65 years 
   
   Total  117,880 (19.9) 121,453 (17.8) 128,832 (17.4) 
   Black women 9,195 (19.2) 9,259 (18.1) 10,501 (18.7) 
   White women 25,908 (15.3) 26,446 (13.2) 27,685 (13.1) 
   Black men 14,876 (20.3) 15,894 (21.1) 18,431 (21.2) 
   White men 65,194 (22.8) 66,229 (19.9) 67,571 (19.0) 




   
   Total  18,765 (3.2) 19,607 (2.9) 20,565 (2.8) 
   Black women 2,364 (4.9) 2,213 (4.3) 2,266 (4.0) 
   White women 5,866 (3.5) 5,849 (2.9) 5,996 (2.8) 
   Black men 2,674 (3.6) 2,905 (3.9) 3,027 (3.5) 
   White men 7,019 (2.5) 7,579 (2.3) 8,097 (2.8) 




   
   Total  16,553 (2.8) 21,429 (3.1) 24,758 (3.3) 
   Black women 2,073 (4.3) 2,228 (4.4) 2,497 (4.4) 
   White women 5,028 (3.0) 5,859 (2.9) 6,283 (3.0) 
   Black men 2,034 (2.8) 2,764 (3.7) 3,515 (4.0) 
   White men 6,866 (2.4) 9,700 (2.9) 11,196 (3.2) 
 
CM: Cardiometabolic. APC: annual percent change. *Indicates that the average APC is significantly 
different from zero, p<0.05. Cardiometabolic diseases are coded as underlying cause of death. Numerator 
(number of premature cardiometabolic deaths) is same as in Table 3. 
 
Table S2. Years of potential life lost before life expectancy from each cardiometabolic disease 
subtype as underlying cause of death, 1999-2018. 
 
 YPLL per 100,000 Average APC in YPLL 
 1999 2011 2018 1999-2011 2011-2018 
Heart disease 
deaths <LE 
     
   Total 1493.5 1079.7 1068.1 -2.7 (-2.9, -2.6)* 0.1 (-0.2, 0.4) 
   Black women 1823.8 1215.5 1208.1 -3.5 (-3.8, -3.3)* -0.1 (-0.7, 0.6) 
   White women 1063.6 753.8 743.5 -2.8 (-3.0, -2.7)* 0.1 (-0.3, 0.6) 
   Black men 2182.7 1549.3 1601.8 -2.7 (-3.3, -2.2)* 0.3 (-0.3, 0.9) 
   White men 1677.2 1243.9 1205.1 -2.5 (-2.6, -2.3)* -0.5 (-0.7, -0.2)* 




     
   Total 254.7 186.4 183.0 -2.7 (-2.9, -2.5)* -0.2 (-0.6, 0.2) 
   Black women 465.1 295.0 267.5 -3.7 (-4.3, -3.0)* -1.4 (-2.3, -0.5)* 
   White women 255.7 181.1 174.8 -3.0 (-3.2, -2.8)* -0.3 (-0.8, 0.2) 
   Black men 389.7 276.6 257.7 -3.1 (-3.7, -2.5)* -0.7 (-1.3, -0.1)* 
   White men 197.6 152.3 156.0 -2.1 (-2.4, -1.9)* 0.4 (-0.3, 1.0) 




     
   Total 204.6 188.1 208.1 -0.9 (-1.4, -0.4)* 1.8 (1.4, 2.3)* 
   Black women 395.0 290.6 298.3 -2.9 (-4.4, -1.4)* 0.6 (0.0, 1.2) 
   White women 185.2 154.9 161.1 -1.7 (-2.3, -1.0)* 0.9 (0.5, 1.4)* 
   Black men 294.4 263.2 312.7 -0.8 (-2.5, 0.9) 2.3 (1.0, 3.7)* 
   White men 176.9 182.4 205.0 0.1 (-0.4, 0.6) 2.1 (1.7, 2.5)* 
 
YPLL: Years of potential life lost. APC: annual percent change. *Indicates that the average APC is 
significantly different from zero, p<0.05. 
 
 
Table S3. Premature deaths (before age 65) attributed to diabetes (as underlying or contributing 
cause) relative to all DM-related deaths and all premature deaths. 
 
 1999 2011 2018 
Number of DM 
deaths <65, N 
   
   Total 43,808 58,530 65,932 
   Black women 5,181 5,704 6,324 
   White women 13,178 16,367 17,432 
   Black men 5,281 7,191 8,475 
   White men 18.703 26,791 30,419 
    
Proportion of all 
DM deaths that are 
<65, % 
   
   Total 20.9 24.5 23.9 
   Black women 27.5 29.9 30.4 
   White women 14.8 17.9 18.2 
   Black men 39.8 42.3 39.7 
   White men 22.5 26.1 24.4 
    
Proportion of all 
<65 deaths that are 
DM-related, %    
   Total 7.4 8.6 8.9 
   Black women 10.8 11.1 11.3 
   White women 7.8 8.2 8.3 
   Black men 7.2 9.5 9.8 
   White men 6.5 8.1 8.6 
 
DM: Diabetes mellitus 
 
Table S4. Years of potential life lost and age-adjusted mortality rates from premature mortality 
(before age 65) from diabetes (as underlying or contributing cause), 1999-2018. 
 
  Average APC 
 1999 2011 2018 1999-2011 2011-2018 
YPLL<65 per 
100,000 from DM 
     
   Total 170.0 173.8 193.8 0.2 (-0.2, 0.6) 1.5 (1.1, 2.0)* 
   Black women 344.9 274.5 296.6 -1.8 (-2.5, -1.0)* 0.8 (-0.1, 1.6) 
   White women 116.4 116.5 127.1 0.0 (-0.4, 0.4) 1.5 (1.0, 2.0)* 
   Black men 437.5 384.7 431.3 -1.0 (-1.6, -0.3)* 1.4 (0.6, 2.2)* 
   White men 172.3 192.0 215.7 0.8 (0.3, 1.3)* 1.7 (1.1, 2.2)* 
      
AAMR<65 per 
100,000 from DM 
     
   Total 18.4 17.7 19.0 -0.4 (-0.7, 0.0)* 1.1 (0.7, 1.5)* 
   Black women 37.2 26.8 26.9 -2.6 (-3.2, -2.1)* 0.0 (-0.7, 0.6) 
   White women 12.7 11.8 12.4 -0.7 (-1.1, -0.3)* 0.8 (0.5, 1.2)* 
   Black men 45.5 39.3 41.3 -1.2 (-2.4, 0.0)* 0.7 (-0.3, 1.8) 
   White men 18.9 19.9 22.1 0.4 (0.0, 0.8)* 1.5 (1.1, 1.9)* 
 
AAMR: age-adjusted mortality rate, APC: annual percent change, DM: diabetes mellitus, YPLL: years of 
potential life lost. 
 
Table S5. Age-adjusted mortality rates from premature cardiometabolic mortality (before age 65) 
by region and by county-level urbanization, 1999-2018. 
 
 AAMR per 100,000 Average APC 
 1999 2011 2018 1999-2011 2011-2018 
Region      
Heart disease      
   Northeast 45.4 31.8 31.1 -3.0 (-3.3, -2.7)* -0.3 (-0.7, 0.1) 
   Midwest 50.6 39.1 39.5 -2.1 (-2.3, -1.9)* 0.0 (-0.2, 0.3) 
   South 56.6 44.4 45.3 -2.0 (-2.4, -1.5)* 0.3 (0.1, 0.6)* 
   West 39.6 29.5 28.4 -2.5 (-2.8, -2.2)* -0.3 (-1.1, 0.4) 
      
Cerebrovascular 
Disease    
  
   Northeast 6.2 4.5 4.2 -2.8 (-3.2, -2.4)* -0.7 (-1.7, 0.2) 
   Midwest 7.2 5.7 5.8 -2.3 (-2.6, -1.9)* 0.3 (-0.5, 1.1) 
   South 9.6 7.5 7.4 -2.1 (-2.2, -1.9)* 0.0 (-0.5, 0.5) 
   West 7.2 5.4 5.4 -2.5 (-2.8, -2.2)* 0.2 (-0.8, 1.2) 
      
Diabetes mellitus      
   Northeast 6.0 5.2 5.5 -1.9 (-2.4, -1.4)* 1.1 (0.0, 2.1)* 
   Midwest 6.7 6.4 7.3 -0.6 (-0.9, -0.3)* 2.2 (1.5, 2.9)* 
   South 8.1 7.7 8.7 -0.6 (-1.1, -0.1) 2.0 (1.6, 2.4)* 
   West 6.1 6 6.6 -0.2 (-1.5, 1.2) 2.3 (1.6, 3.1)* 
      
Rurality      
Heart disease      
   Urban 47.9 35.6 35.5 -2.4 (-2.5, -2.3)* -0.1 (-0.3, 0.1) 
   Rural 56.5 48.2 50.3 -1.4 (-1.6, -1.2)* 0.8 (0.5, 1.1)* 
      
Cerebrovascular 
disease    
  
   Urban 7.7 5.9 5.8 -2.3 (-2.6, -2.1)* -0.1 (-0.7, 0.4) 
   Rural 8.5 7.1 7.5 -1.6 (-1.9, -1.3)* 1.1 (0.4, 1.8)* 
      
Diabetes mellitus      
   Urban 6.8 6.2 6.9 -1.0 (-1.9, -0.1)* 1.7 (1.4, 2.1)* 
   Rural 7.5 8.5 10.1 0.7 (-0.3, 1.8) 3.1 (2.4, 3.8)* 
 
AAMR: age-adjusted mortality rate, APC: annual percent change 
 
 
Table S6. Age-adjusted mortality rates from premature cardiometabolic mortality (before age 65) 
by region and county-level urbanization, 1999-2018. 
 
 AAMR per 100,000 Average APC 
 1999 2011 2018 1999-2011 2011-2018 
Heart disease      
Northeast      
   Urban 45.2 31.3 30.6 -3.0 (-3.2, -2.7)* -0.4 (-0.8, 0.0)* 
   Rural 47.2 36.8 36.8 -2.4 (-3.0, -1.9)* 0.7 (-0.1, 1.5) 
Midwest      
   Urban 51.1 38.7 38.7 -2.2 (-2.5, -2.0)* -0.2 (-0.5, 0.1) 
   Rural 48.9 40.6 42.3 -1.6 (-1.8, -1.4)* 0.9 (0.5, 1.2)* 
South      
   Urban 53.1 40.6 41.5 -2.3 (-2.4, -2.1)* 0.4 (0.0, 0.8)* 
   Rural 70.5 62.1 65.5 -1.1 (-1.3, -0.8)* 0.9 (0.6, 1.3)* 
West      
   Urban 39.7 29.1 27.8 -2.6 (-2.9, -2.2)* -0.4 (-1.3, 0.4) 
   Rural 39.0 33.1 33.8 -1.5 (-1.9, -1.1)* 0.5 (-0.5, 1.4) 
      
Cerebrovascular 
Disease    
  
Northeast      
   Urban 6.2 4.5 4.2 -2.8 (-3.2, -2.5)* -0.9 (-1.7, 0.0)* 
   Rural 5.7 4.5 4.5 -1.2 (-1.5, -0.8)* 1.2 (-1.5, -0.8)* 
Midwest      
   Urban 7.4 5.8 5.7 -2.5 (-2.8, -2.1)* 0.0 (-0.8, 0.9) 
   Rural 6.8 5.5 5.9 -1.6 (-2.2, -1.0)* 0.5 (-0.2, 1.2) 
South      
   Urban 9.1 7.0 6.9 -2.3 (-2.8, -1.7)* 0.0 (-0.4, 0.5) 
   Rural 11.3 9.7 10.0 -1.4 (-1.6, -1.1)* 1.1 (0.2, 1.9)* 
West      
   Urban 7.3 5.4 5.4 -2.6 (-2.9, -2.3)* 0.1 (-0.9, 1.2) 
   Rural 6.6 5.1 6.0 -2.2 (-3.1, -1.3)* 2.6 (0.3, 0.5)* 
      
Diabetes mellitus      
Northeast      
   Urban 6 5.1 5.4 -1.9 (-3.5, -0.2)* 1.1 (0.5, 1.8)* 
   Rural 5.8 6.5 6.5 0.1 (-0.6, 0.7) 0.1 (-0.6, 0.7) 
Midwest      
   Urban 6.8 6.3 6.8 -0.9 (-1.3, -0.6)* 1.7 (0.7, 2.6)* 
   Rural 6.5 7 8.8 0.2 (-0.3, 0.7) 3.6 (2.3, 5.0)* 
South      
   Urban 7.9 7.1 7.9 -1.1 (-1.6, -0.5)* 1.6 (1.1, 2.1)* 
   Rural 8.9 10.8 13.0 1.4 (0.2, 2.6)* 3.1 (2.5, 3.7)* 
West      
   Urban 6.1 5.9 6.5 -0.3 (-1.6, 1.0) 2.2 (1.5, 2.9)* 
   Rural 6.6 6.7 7.3 1.0 (0.3, 1.7)* .0 (0.3, 1.7)* 
 
AAMR: age-adjusted mortality rate, APC: annual percent change 
 
Figure S1. Age adjusted mortality rates from premature cardiometabolic mortality before age 65, 
1999-2018. 
 




























































































































































































Figure S2. Age adjusted mortality rates from premature cardiometabolic mortality by region and 
county-level urbanization, 1999-2018. 
 
AAMR: Age-adjusted mortality rates. 
A. Heart disease - Urban
C. Cerebrovascular disease - Urban
































































































































































































































































































































































































Northeast Midwest South West
B. Heart disease - Rural
D. Cerebrovascular disease - Rural
F. Diabetes mellitus - Rural
